The novel myokine irisin: clinical implications and potential role as a biomarker for sarcopenia in postmenopausal women
- 101 Downloads
To clarify the association of circulating irisin with muscle, liver and bone, and to evaluate irisin as a biomarker for sarcopenia in postmenopausal women.
Quadriceps cross-sectional area (QcCSA), bone mineral density (BMD), liver attenuation (measured in Hounsfield units (HU)) were assessed using quantitative computed tomography in 153 postmenopausal women, mean age of 72.20 ± 5.96 years. Muscle strength and physical performance were evaluated by handgrip test and short physical performance battery, respectively. Serum irisin was measured by an enzyme-linked immunosorbent assay kit. In addition, 147 young women were recruited as a reference group to define cut-off values for sarcopenia.
Circulating irisin was positively correlated with QcCSA/body weight (BW) and liver HU even after adjusting for multiple covariates, and the serum level was significantly lower in the sarcopenia group (QcCSA/BW<−2SD of the mean values for young women) than in the presarcopenia (−2SD≤QcCSA/BW<−1SD) or control groups (1SD≤QcCSA/BW<2SD). Logistic regression models showed that the relationship between circulating irisin and prevalence of sarcopenia remained significant after adjusting for confounding factors (per 1.0 ng/mL decrease of irisin, odds-ratio = 1.95, 95% confidence interval 1.33–2.87, p-value = 0.001).
In postmenopausal women, serum irisin may be used as a biomarker for sarcopenia, and we showed the potential for the development of irisin-based early screening and staging tool for sarcopenia.
KeywordsIrisin Sarcopenia Aging Screening
This work was partially supported by the National Research Foundation of Korea (grant number NRF-2014R1A2A1A11053818).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 1.A.J. Cruz-Jentoft, J.P. Baeyens, J.M. Bauer, Y. Boirie, T. Cederholm, F. Landi, F.C. Martin, J.P. Michel, Y. Rolland, S.M. Schneider, E. Topinkova, M. Vandewoude, M. Zamboni, P., European Working Group on Sarcopenia in Older, Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 39(4), 412–423 (2010)CrossRefGoogle Scholar
- 4.M. Cesari, R.A. Fielding, M. Pahor, B. Goodpaster, M. Hellerstein, G.A. van Kan, S.D. Anker, S. Rutkove, J.W. Vrijbloed, M. Isaac, Y. Rolland, C. M’Rini, M. Aubertin-Leheudre, J.M. Cedarbaum, M. Zamboni, C.C. Sieber, D. Laurent, W.J. Evans, R. Roubenoff, J.E. Morley, B. Vellas, S. International Working Group on, Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia. J. Cachex. Sarcopenia Muscle 3(3), 181–190 (2012)CrossRefGoogle Scholar
- 5.P. Lee, J.D. Linderman, S. Smith, R.J. Brychta, J. Wang, C. Idelson, R.M. Perron, C.D. Werner, G.Q. Phan, U.S. Kammula, E. Kebebew, K. Pacak, K.Y. Chen, F.S. Celi, Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans. Cell. Metab. 19(2), 302–309 (2014)CrossRefGoogle Scholar
- 7.S. Pekkala, P.K. Wiklund, J.J. Hulmi, J.P. Ahtiainen, M. Horttanainen, E. Pollanen, K.A. Makela, H. Kainulainen, K. Hakkinen, K. Nyman, M. Alen, K.H. Herzig, S. Cheng, Are skeletal muscle FNDC5 gene expression and irisin release regulated by exercise and related to health? J. Physiol. 591(21), 5393–5400 (2013)CrossRefGoogle Scholar
- 8.M.J. Lee, S.A. Lee, B.Y. Nam, S. Park, S.H. Lee, H.J. Ryu, Y.E. Kwon, Y.L. Kim, K.S. Park, H.J. Oh, J.T. Park, S.H. Han, D.R. Ryu, S.W. Kang, T.H. Yoo, Irisin, a novel myokine is an independent predictor for sarcopenia and carotid atherosclerosis in dialysis patients. Atherosclerosis 242(2), 476–482 (2015)CrossRefGoogle Scholar
- 10.A. Palermo, R. Strollo, E. Maddaloni, D. Tuccinardi, L. D’Onofrio, S.I. Briganti, G. Defeudis, M.De Pascalis, M.C. Lazzaro, G. Colleluori, S. Manfrini, P. Pozzilli, N. Napoli, Irisin is associated with osteoporotic fractures independently of bone mineral density, body composition or daily physical activity. Clin. Endocrinol. 82(4), 615–619 (2015)CrossRefGoogle Scholar
- 18.J.M. Guralnik, E.M. Simonsick, L. Ferrucci, R.J. Glynn, L.F. Berkman, D.G. Blazer, P.A. Scherr, R.B. Wallace, A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J. Gerontol. 49(2), M85–M94 (1994)CrossRefGoogle Scholar
- 21.J.S. Chang, T.H. Kim, T.T. Nguyen, K.S. Park, N. Kim, I.D. Kong, Circulating irisin levels as a predictive biomarker for sarcopenia: A cross-sectional community-based study. Geriatr. Gerontol. Int. https://doi.org/10.1111/ggi.13030 (2017)
- 24.J.M. Moreno-Navarrete, F. Ortega, M. Serrano, E. Guerra, G. Pardo, F. Tinahones, W. Ricart, J.M. Fernández-Real, Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J. Clin. Endocrinol. & Metab. 98(4), E769–E778 (2013)CrossRefGoogle Scholar
- 25.J.Y. Huh, G. Panagiotou, V. Mougios, M. Brinkoetter, M.T. Vamvini, B.E. Schneider, C.S. Mantzoros, FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism 61(12), 1725–1738 (2012)CrossRefGoogle Scholar